CNDAC Continuous Infusion Dosage Regimen for Antitumor Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antitumor agents like CNDAC face challenges in achieving a high antitumor effect while minimizing toxicity and side effects, particularly body weight suppression and leucopenia, which limits the duration of continuous administration in cancer treatment.
Innovation Solution
Administering 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone (CNDAC) through continuous intravenous infusion at doses of 2.0 to 4.0 mg/m² per day for 168 to 336 hours, allowing for prolonged patient survival with reduced risk of side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CNDAC is administered by continuous intravenous infusion to achieve high antitumor effect, then patient survival is prolonged, but toxicity and side effects (body weight suppression and leucopenia) increase
Solution Approach 1:
The patent applies parameter changes by modifying the administration method from intermittent injection to continuous intravenous infusion, and by optimizing the dosage range (2.0-4.0 mg/m²/day). This continuous low-dose administration maintains effective drug concentration in the bloodstream while avoiding the peak toxicity associated with intermittent high-dose administration, thereby resolving the contradiction between antitumor efficacy and toxicity
Solution Approach 2:
The patent implements continuity of useful action through continuous intravenous infusion over extended periods (168-336 hours). This ensures constant delivery of the antitumor agent to maintain therapeutic effect while allowing the body to adapt to sustained low-level drug presence, reducing acute toxic reactions and enabling prolonged treatment courses that improve survival without excessive cumulative toxicity
2Productivity
If CNDAC is administered at higher doses to enhance antitumor effect, then tumor cell killing is improved, but side effects such as body weight suppression and leucopenia worsen
Solution Approach 1:
The patent changes the dosage parameter from conventional higher intermittent doses to lower continuous doses (2.0-4.0 mg/m²/day). This parameter optimization maintains sufficient pharmacological activity to kill tumor cells while staying below the threshold that triggers severe side effects like body weight suppression and leucopenia, thus resolving the contradiction between productivity and harmful factors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves a high antitumor effect while minimizing side effects such as body weight suppression and leucopenia, enabling prolonged treatment and improved patient survival without interrupting medication due to toxicity.
Implementation Method 1
it is considered that CNDAC is phosphorylated by intracellular deoxycytidine kinase, and thereby a triphosphorylated form (CNDACTP) is provided
Implementation Method 2
CNDACTP is incorporated into a DNA strand, thus inducing hydrolysis and breaking the DNA strand
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Antitumor treatment regimens comprising: administering, to a patient diagnosed with cancer, an antitumor agent comprising 4-amino-1-(2-cyano-2-deoxy-ß-D-arabinofuranosyl)-2(1H)-pyrimidinone, or a salt thereof, by way of continuous intravenous infusion, in an amount of 2.0 to 4.0 mg per m2 total body surface area of the patient, of 4-amino-1-(2-cyano-2-deoxy-ß-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours. Compositions for providing the methods are also disclosed.